Lymphocyte micronuclei frequencies in skin, haematological, prostate, colorectal and esophageal cancer cases: A systematic review and meta-analysis

IF 6.4 2区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Mutation Research-Reviews in Mutation Research Pub Date : 2021-01-01 DOI:10.1016/j.mrrev.2021.108372

Varinderpal S. Dhillon , Permal Deo , Stefano Bonassi , Michael Fenech

{"title":"Lymphocyte micronuclei frequencies in skin, haematological, prostate, colorectal and esophageal cancer cases: A systematic review and meta-analysis","authors":"Varinderpal S. Dhillon , Permal Deo , Stefano Bonassi , Michael Fenech","doi":"10.1016/j.mrrev.2021.108372","DOIUrl":null,"url":null,"abstract":"<div><p><span>Micronucleus (MN) assay has been widely used as a biomarker of DNA damage, chromosomal instability, cancer risk and accelerated aging in many epidemiological studies. In this narrative review and meta-analysis we assessed the association between lymphocyte micronuclei (MNi) and cancers of the skin, blood, digestive tract, and prostate. The review identified nineteen studies with 717 disease subjects and 782 controls. Significant increases in MRi for MNi were observed in the following groups: subjects with blood cancer (MRi = 3.98; 95 % CI: 1.98–7.99; p = 0.000) and </span>colorectal cancer (excluding IBD) (MRi = 2.69; 95 % CI: 1.82–3.98, p < 0.000). The results of this review suggest that lymphocyte MNi are a biomarker of DNA damage and chromosomal instability in people with haematological or colorectal cancers. However, the MRi for lymphocyte MNi in subjects with cancers of skin, prostate, esophagus was not significantly increased. More case-control and prospective studies are warranted to further verify the observed trends and to better understand the role of lymphocyte MNi as a biomarker of cancer risk in blood, skin, digestive tract and prostate.</p></div>","PeriodicalId":49789,"journal":{"name":"Mutation Research-Reviews in Mutation Research","volume":"787 ","pages":"Article 108372"},"PeriodicalIF":6.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.mrrev.2021.108372","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mutation Research-Reviews in Mutation Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1383574221000090","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

Micronucleus (MN) assay has been widely used as a biomarker of DNA damage, chromosomal instability, cancer risk and accelerated aging in many epidemiological studies. In this narrative review and meta-analysis we assessed the association between lymphocyte micronuclei (MNi) and cancers of the skin, blood, digestive tract, and prostate. The review identified nineteen studies with 717 disease subjects and 782 controls. Significant increases in MRi for MNi were observed in the following groups: subjects with blood cancer (MRi = 3.98; 95 % CI: 1.98–7.99; p = 0.000) and colorectal cancer (excluding IBD) (MRi = 2.69; 95 % CI: 1.82–3.98, p < 0.000). The results of this review suggest that lymphocyte MNi are a biomarker of DNA damage and chromosomal instability in people with haematological or colorectal cancers. However, the MRi for lymphocyte MNi in subjects with cancers of skin, prostate, esophagus was not significantly increased. More case-control and prospective studies are warranted to further verify the observed trends and to better understand the role of lymphocyte MNi as a biomarker of cancer risk in blood, skin, digestive tract and prostate.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

皮肤、血液癌、前列腺癌、结直肠癌和食管癌病例中淋巴细胞微核频率的系统回顾和meta分析

微核(MN)测定在许多流行病学研究中被广泛用作DNA损伤、染色体不稳定性、癌症风险和加速衰老的生物标志物。在这篇叙述性回顾和荟萃分析中，我们评估了淋巴细胞微核(MNi)与皮肤、血液、消化道和前列腺癌之间的关系。该综述确定了19项研究，涉及717名疾病受试者和782名对照。MRi检测MNi在以下组中显著升高:血癌患者(MRi = 3.98;95% ci: 1.98-7.99;p = 0.000)和结直肠癌(不包括IBD) (MRi = 2.69;95% CI: 1.82-3.98, p < 0.000)。本综述的结果表明，淋巴细胞MNi是血液病或结直肠癌患者DNA损伤和染色体不稳定的生物标志物。然而，皮肤癌、前列腺癌、食道癌患者的淋巴细胞MNi的MRi检查没有明显升高。需要更多的病例对照和前瞻性研究来进一步验证观察到的趋势，并更好地了解淋巴细胞MNi作为血液、皮肤、消化道和前列腺中癌症风险的生物标志物的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Mutation Research-Reviews in Mutation Research 生物-毒理学

CiteScore

12.20

自引率

1.90%

发文量

审稿时长

15.7 weeks

期刊介绍： The subject areas of Reviews in Mutation Research encompass the entire spectrum of the science of mutation research and its applications, with particular emphasis on the relationship between mutation and disease. Thus this section will cover advances in human genome research (including evolving technologies for mutation detection and functional genomics) with applications in clinical genetics, gene therapy and health risk assessment for environmental agents of concern.